Nurexone Biologic Inc · TSXV:NRX
Nurexone Biologic — Investor Presentation (September 2026)
18 slides from Nurexone Biologic's investor presentation, September 2026
Slide 1: Where Nature Ends, NurExone Begins
WHERE NATURE ENDS, NUREXONE BEGINS. Regenerative medicine for central nervous system injuries NUREXONE BIOLOGIC TSXV: NRX | OTCQB: NRXBF | FSE: J90 Q3 2026
Slide 2: Disclaimer
DISCLAIMER Contents of this presentation are provided for general information purposes only and do not constitute an offer to sell or solicitation of an offer to buy any security in any jurisdiction. This presentation contains “forward-looking information” for purposes of applicable securities laws
Slide 3: A Biological Divide: The Central Nervous System Can't Repair
A BIOLOGICAL DIVIDE SOME NERVES REPAIR NATURALLY. THE CENTRAL NERVOUS SYSTEM CAN’T PERIPHERAL NERVES CENTRAL NERVOUS SYSTEM The adult central nervous system has very limited natural regenerative capacity. 3
Slide 4: What Needs To Be Done?
T H E S C IEN T IFIC G O A L WHAT NEEDS TO BE DONE? “The best way to restore function after spinal cord injury is to find ways to regenerate the [neural] connections that are broken.” Reeve-Irvine Research Center Source: Reeve-Irvine Research Center 4
Slide 5: Regenerate. Rewire. Recover.
T H E I D EA REGENERATE. REWIRE. RECOVER. NurExone is developing minimally invasive exosome-based regenerative therapies for central nervous system injuries. 6
Slide 6: The Consequence: ~30,000 Acute Spinal Cord Injuries Each Year
THE CONSEQUENCE A traumatic injury happens ~30,000 people in a moment. in North America and Europe incur ✦ ⌁ acute spinal cord injuries (SCI) each A FALL A CRASH A SPORTS INJURY year. The damage can last a lifetime Staggering healthcare, household and personal costs • 18000 new cases in the US • 11,
Slide 7: Exosomes: Nature's Targeted Delivery System
EXOSOMES NATURE’S TARGETED DELIVERY SYSTEM. Exosomes are natural, acellular biological nanoparticles used in cell-to-cell communication. Tiny cell-free nanoparticles that can cross the Blood-Brain Barrier MSC exosomes have natural “homing” capabilities to sites of injury/inflammation. Loadable with
Slide 8: ExoTherapy: Converting Exosomes to Therapeutics
NUREXONE TECHNOLOGY ExoTherapy: Converting Exosomes to Therapeutics + → Exosomes siRNA ExoPTEN INHERENT LOADING OF REGENERATIVE HEALING THERAPEUTIC PROPERTIES MOLECULE THERAPY ExoPTEN — lead investigational exosome-based nanodrug candidate 7
Slide 9: ExoPTEN: One Candidate, Multiple High-Impact Indications
EXOPTEN: ONE INVESTIGATIONAL CANDIDATE. MULTIPLE HIGH-IMPACT INDICATIONS UNDER STUDY. SPINAL CORD Functional + biological evidence OPTIC NERVE Retinal function + neuronal survival FACIAL NERVE Exploratory research Programs shown reflect current preclinical and exploratory research in NurExone materi
Slide 10: Preclinical Evidence: ExoPTEN for Acute Spinal Cord Injury
P R EC L I N I C A L E V I D E N C E - E xo P T E N fo r A c u te S p i n a l C o rd I n j u r y 100% of animals in the higher dose group regained measurable walking ability after minimally invasive treatment. Gait recovery measured with CatWalk XT. PRECLINICAL VIDEO EVIDENCE High dose: 6/6 animals
Slide 11: Preclinical Evidence: Structural Repair
P R EC L I N I C A L E V I D E N C E - E xo P T E N fo r A c u te S p i n a l C o rd I n j u r y Structural Repair MRI OF SPINE Source: July 2025 ExoPTEN dose-ranging preclinical study. Animal data; not indicative of human efficacy. 10
Slide 12: Optic Nerve Damage: A Second CNS Indication
Multiple High-Impact Indications OPTIC NERVE DAMAGE (OND) - A SECOND CNS INDICATION. $2.5–4B PRECLINICAL EVIDENCE ESTIMATED COMBINED BASE PEAK TAM* IN COLLABORATION WITH SHEBA MEDICAL CENTER PACG NAION / AION MS-ON 75% Different diseases. FUNCTIONAL RECOVERY One shared target: the damaged optic nerv
Slide 13: A Second Value Engine: Same Exosomes, Another Market
A SECOND VALUE ENGINE SAME EXOSOMES - ANOTHER MARKET. NurExone is building a U.S. based commercial platform for MSC-derived naïve exosomes — alongside its therapeutic development. PRODUCE. SUPPLY. SCALE. A nearer-term commercial opportunity built on the same NAÏVE EXOSOMES FOR: exosome manufacturing
Slide 14: Where We Are, Moving Forward: 2027 Objectives
WHERE WE ARE MOVING FORWARD SCIENCE REGULATORY MANUFACTURING COMMERCIAL FINANCIAL ✓ ✓ FDA + EMA ✓ U.S. GMP ✓ ✓ PRECLINICAL ORPHAN DRUG PATHWAY FIRST US$20M+ EVIDENCE DESIGNATION FOR (Made Scientific PARTNERSHIPS RAISED ACUTE SCI MOU) 2027 Objectives THERAPEUTICS COMMERCIAL CAPITAL MARKETS DEFINITIVE
Slide 15: Corporate Structure
CORPORATE STRUCTURE NurExone Biologic Inc. TSXV: NRX · OTCQB: NRXBF · FSE: J90 94.45M shares outstanding as of June 30, 2026 100% NurExone Biologic Ltd. Exo-Top REGENERATIVE THERAPEUTICS COMMERCIAL EXOSOMES Cells & exosomes R&D · product development U.S. commercial supply product production
Slide 16: Strong Team Invested in the Outcome
COMPANY OVERVIEW STRONG TEAM INVESTED IN THE OUTCOME. 25% FOUNDER OWNERSHIP US$20M+ RAISED SINCE INCEPTION 5 PATENT FAMILIES FDA + EMA ORPHAN DRUG DESIGNATIONS FOUNDED FROM TECHNION 2020 & TAU NurExone Biologic | TSXV: NRX · OTCQB: NRXBF · FSE: J90
Slide 17: The NurExone Story Is Moving
GLOBAL MEDIA MOMENTUM THE NUREXONE STORY IS MOVING. VISIBILITY IS BUILDING AS THE NEXT MILESTONES APPROACH. Selected editorial coverage and platform visibility; distribution/profile platforms are shown separately.
Slide 18: Why NurExone?
Why NurExone? • HUGE UNMET NEED : CNS injuries with limited natural regeneration • DIFFERENTIATED TECHNOLOGY: Exosome + cargo + proprietary loading • PRECLINICAL EVIDENCE: Functional and biological results across CNS models • MULTIPLE VALUE DRIVERS: Therapeutics and commercial exosomes • MANUFACTURI
NurExone Biologic — Investor Presentation (September 2026) on 6ix